S100A2 Antibody

1. S100A2 and S100P can be used as specific duct markers in eccrine sweat glands, and combined use of S100P or S100A2 with keratins enables easy to distinction between secretory coils and ducts. PMID: 28353163
2. These results indicate that oxidative stress impairs the ability of S100 proteins to bind and activate PP5, which in turn modulates the ASK1-mediated signaling cascades involved in apoptosis. PMID: 27600583
3. high S100A2 expression and NSCLC PMID: 27876462
4. Our results indicate that serum levels of S100A2 and S100A6 are significantly elevated in early stage non-small cell lung cancer PMID: 26361956
5. S100A2 could have a role in poor prognosis in stage II and III colorectal cancer recurrence PMID: 26783118
6. The potential of cytoplasmic S100A2 overexpression as a predictor of recurrence risk in oral squamous cell carcinoma patients. PMID: 25591983
7. Data show higher expression level of S100A2 in high-invasive cholangiocarcinoma Cell Line suggesting it as potential marker of tumor progression and novel therapeutic target. PMID: 25999659
8. Our investigation complements the current understanding of laryngeal cancer progression. Furthermore, this study supports the concept that enhanced expression of S100A2 may be a promising strategy in developing novel cancer therapeutic drugs. PMID: 25874882
9. These data demonstrate the importance of S100A2 downstream of the BRCA1/DeltaNp63 signalling axis in modulating transcriptional responses and enforcing growth control mechanisms through destabilisation of mutant p53. PMID: 24556685
10. loss of S100A2 expression contributes to Ggastric cancer development and progression. PMID: 24318973
11. S100A2 protumorigenic actions and its involvement in TGF-beta-mediated cancer cell invasion and epithelial-mesenchymal transition. PMID: 23996929
12. Expression of S100A2 in cholangiocarcinoma cells significantly correlated with the histological grade, lymph node metastasis, clinical stage, and a poor survival rate of the patients. Thus it is a strong tumor marker for the cancer. PMID: 23621473
13. Data indicate that S100A2 expression predicts longer disease-free survival (DFS) and overall survival (OS) in patients treated with adjuvant therapy and should be evaluated as a predictive biomarker. PMID: 23726265
14. In conclusion, data from the present study demonstrated that loss of S100A2 expression contributes to gastric cancer development and progression PMID: 23337980
15. Data indicate S100A2 and S100P proteins as novel Ca2+-dependent regulators of the CHIP-proteasome pathway. PMID: 23344957
16. findings highlight an important link between the TGF-beta1-induced MAPK and p53 signalling pathways in the regulation of S100A2 expression and pro-tumorigenic actions PMID: 22747445
17. Loss of Reprimo and S100A2 expressions occurs frequently in gastric adenocarcinomas. The expressions of Reprimo and S100A2 may be potential biomarkers for gastric adenocarcinomas detection. PMID: 20949468
18. The coding sequence polymorphism S100A2_185G>A had no regulatory role in S100A2-mediated tumor suppression in oral cancer. PMID: 21029261
19. S100A2 is upregulated in gastric adenocarcinoma and is associated with tumor progression. PMID: 21443102
20. Although the diffraction data of S100A2 were recorded at a wavelength of 0.90 A, which is usually not assumed to be suitable for calcium/sulfur SAD, the anomalous signal was satisfactory. PMID: 20823519
21. decrease in S100A2 staining from normal to cancer cases is more pronounced in glandular than in squamous epithelial tissue PMID: 11813862
22. Expression of S100A2 protein in squamous cell carcinoma of the esophagus PMID: 11956617
23. DeltaNp63 transactivated the S100A2 promoter, and significantly more fold changes were seen in DeltaNp63-introduced cells than in p53-introduced cells, suggesting that DeltaNp63 may be a novel stimulator of the S100A2 promoter. PMID: 14519656
24. Strong S100A2 expression was often associated with increasing levels of disorder in preinvasive bronchial lesions in non-small cell lung cancer. PMID: 15467767
25. in oral cancer cells the Ca(2+)- and cell cycle-dependent p53-S100A2 interaction might modulate proliferation PMID: 15941720
26. The five genes, and three of the encoded proteins, were shown differentially expressed between a group of keratoconus patients and a reference group using different techniques PMID: 16015083
27. abnormal transcription of TACSTD2 and S100A2 are thought to be unique molecular markers of the preinvasive stage of lung adenocarcinoma PMID: 16232198
28. S100A2 expression was demonstrated to be the only independent factor for late cervical metastasis. PMID: 16273244
29. Involvement of S100A2 and S100A4 in the progression of lung adenocarcinomas provides a list of targets regulated by S100A2 and S100A4. PMID: 16367903
30. S100A2 gene, whose transcript and protein are induced during keratinocyte differentiation, is a direct transcriptional target of p73beta and DeltaNp63alpha and is required for proper keratinocyte differentiation PMID: 16449968
31. results demonstrate frequent cytosolic overexpression of S100A2 and S100A4 in Barrett's adenocarcinoma PMID: 17032501
32. Increased S100 A2 expression is associated with non-small cell lung cancer PMID: 17067748
33. Preliminary analysis of the X-ray data indicates that there are two subunits per asymmetric unit. PMID: 17077493
34. S100A2 was down-regulated in lymph node metastasis of squamous cell carcinoma, head and neck neoplasms (SCCHN), suggesting that instead of being a putative tumor suppressor, S100A2 may play a role in the metastasis of SCCHN PMID: 17123307
35. Zn2+ might deactivate S100A2 by inhibiting response to intracellular Ca2+ signals PMID: 17239974
36. STMN1, but not SYK or S100A2, have roles in preventing progression of ER-positive primary breast cancer PMID: 17874182
37. Gene regulation is mediated by a novel transcriptional element in the S100A2 promoter which is bound by TAp63gamma but not by p53. PMID: 18388131
38. Analysis of S100A2 expression revealed that expression in adenocarcinomas and squamous cell carcinomas is significantly different, but not related to any of the found alterations. PMID: 18656279
39. S100A2 and S100A6 interact with another TPR protein Tom70 and regulate the Tom70-ligand interaction in vitro PMID: 18669640
40. Survival after UVA irradiation was greater in human keratinocytes compared to mouse skin with no S100A2 expression, showing a protective role for S100A2. A S100A2-dependent difference was observed in the induction of Cxcl13 transcripts in transgenic mice. PMID: 18773213
41. These findings identify S100A2 as a strong metastasis inducer in vivo. PMID: 19118029
42. Diminished expression of S100A2, a putative tumor suppressor, is an independent predictive factor of neck node relapse in laryngeal squamous cell carcinoma. PMID: 19344608
43. S100A2 expression is a good predictor of response to pancreatectomy for Pancreatic Cancer and suggests that high S100A2 expression may be a marker of a metastatic phenotype. PMID: 19376121
44. S100A2 and p63 protein both play important roles in the carcinogenesis of esophageal squamous cell carcinoma (ESCC). An investigation into the combined expression of S100A2 and p63 may be helpful in early diagnosis. PMID: 19725154

Show More

Hide All

HGNC: 10492

OMIM: 176993

KEGG: hsa:6273

STRING: 9606.ENSP00000357697

UniGene: Hs.516484